Results 11 to 20 of about 9,191 (255)

A Narrative Literature Review of the Established Safety of Human Serum Albumin Use as a Stabilizer in Aesthetic Botulinum Toxin Formulations Compared to Alternatives [PDF]

Toxins, 2023
Despite more than 80 years of use in a number of conditions, including in critically ill patients, comments have recently arisen regarding the safety and efficacy of human serum albumin (HSA) as a therapeutic product and stabilizer/excipient in botulinum
Sonja Sattler, Stephen Gollomp, Andrew Curry   +2 more
doaj   +2 more sources

Allergy to polyethylene glycol and polysorbates in a patient cohort: Diagnostic work‐up and decision points for vaccination during the COVID‐19 pandemic

Clinical and Translational Allergy, 2022
Background During the COVID‐19 pandemic focus has been on polyethylene glycol (PEG) and polysorbate as these excipients are constituents in the first vaccines and possible elicitors of allergic reactions to the vaccines.
Charlotte G. Mortz, Henrik F. Kjaer, Trine H. Rasmussen, Helene M. Rasmussen, Lene Heise Garvey, Carsten Bindslev‐Jensen   +5 more
doaj   +2 more sources

Natural products and polysorbates: Potential Inhibitors of biofilm formation in Pseudomonas aeruginosa

Journal of Infection in Developing Countries, 2020
Introduction: With all the challenges super bugs are imposing, biofilm formation opens the door against various more complicated challenges. Such issue may be highlighted with the ability of the latter to render the antibiotics hardly accessible to ...
Mariam Miari, Sari S Rasheed, Nathaline Haidar Ahmad, Dana Itani, Antoine Abou Fayad, Ghassan M Matar   +5 more
doaj   +2 more sources

Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates

Pharmaceutics, 2022
Given their safety and efficiency in protecting protein integrity, polysorbates (PSs) have been the most widely used excipients for the stabilization of protein therapeutics for years.
Angel J. Castañeda Ruiz, Maryam A. Shetab Boushehri, Tamara Phan, Stefan Carle, Patrick Garidel, Julia Buske, Alf Lamprecht   +6 more
doaj   +2 more sources

Investigation on the Combined Effect of Hydroxypropyl Beta-Cyclodextrin (HPβCD) and Polysorbate in Monoclonal Antibody Formulation [PDF]

Pharmaceuticals
Monoclonal antibodies require careful formulation due to their inherent stability limitations. Polysorbates are commonly used to stabilize mAbs, but they are prone to degradation, which results in unwanted impurities.
Jiayi Huang, Shiqi Hong, Lucas Yuan Hao Goh, Hailong Zhang, Tao Peng, Keat Theng Chow, Rajeev Gokhale, Vinod Tuliani   +7 more
doaj   +2 more sources

Comparative Stability Study of Polysorbate 20 and Polysorbate 80 Related to Oxidative Degradation

Pharmaceutics, 2023
The surfactants polysorbate 20 (PS20) and polysorbate 80 (PS80) are utilized to stabilize protein drugs. However, concerns have been raised regarding the degradation of PSs in biologics and the potential impact on product quality.
Benedykt Kozuch, Johanna Weber, Julia Buske, Karsten Mäder, Patrick Garidel, Tim Diederichs   +5 more
doaj   +4 more sources

Phosphatidylcholine-Polysorbate 20-Based Mixed Micelles: A New Option to Prevent Protein Aggregation? [PDF]

Pharmaceutics
Background/Objectives: Surfactants are commonly used to protect proteins from denaturation and particle formation, thereby ensuring the long-term stability of biopharmaceuticals.
Johanna Weber, Tim Diederichs, Lukas Bollenbach, Patrick Garidel, Karsten Mäder   +4 more
doaj   +2 more sources

Comparison of the NMR and the Acid Value Determination Methods for Quality Control of Input Polysorbates

Acta Chimica Slovenica, 2019
Polysorbates (PS) are the most common non-ionic surfactants used in protein formulations. Their degradation has been studied intensively in recent years.
Ema Valentina Brovč, Stane Pajk, Roman Šink, Janez Mravljak   +3 more
doaj   +2 more sources

Pediatric Safety of Polysorbates in Drug Formulations [PDF]

Children, 2019
Polysorbates 20 and 80 are the most frequently used excipients in biotherapeutics, the safety data for which have been well documented in adults. The polysorbate content in therapeutic formulations that are administered to children, however, has been less clearly regulated or defined with regard to safety.
Christina Kriegel, Matthias Festag, Ravuri S.K. Kishore, Dieter Roethlisberger, Georg Schmitt   +4 more
openaire   +3 more sources

Immunological Considerations of Polysorbate as an Excipient in Botulinum Neurotoxin Type A Formulations: A Narrative Review [PDF]

Toxins
Recent botulinum neurotoxin type A (BoNT/A) formulations have shifted towards the use of polysorbate 20 (PS20) and polysorbate 80 (PS80) as a non-human-derived excipient to enhance product stability.
Michael Uwe Martin, Jürgen Frevert, Je-Young Park, Haiyan Cui, Andy Curry, Wei Qi Loh   +5 more
doaj   +2 more sources